drugset / Trial / NCT04076371

The Treatment Efficacy of Combination Atypical Antipsychotics With Sertraline in Patients With Schizophrenia

NCT04076371 ↗

Completed 1640 enrolled Beijing HuiLongGuan Hospital
RandomizedParallel-groupSingle-blindTreatment

Summary

A randomized, double-blind trial of the treatment effect of dose-low antipsychotics combined with low-dose sertraline in 1640 schizophrenia patients

Timeline

Start
2012-01
Primary completion
2018-12
Completion
2018-12

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Olanzapine Small molecule 7.5 mg —
Subject Olanzapine Small molecule 10 mg —
Subject Olanzapine Small molecule 12.5 mg —
Subject Olanzapine Small molecule 20 mg —
Subject Paliperidone Unknown 3 mg —
Subject Paliperidone Unknown 4.5 mg —
Subject Paliperidone Unknown 6 mg —
Subject Paliperidone Unknown 9 mg —
Subject Risperidone Other / unclassified 2 mg —
Subject Risperidone Other / unclassified 3.5 mg —
Subject Risperidone Other / unclassified 4 mg —
Subject Risperidone Other / unclassified 6 mg —
Subject Sertraline Small molecule 50 mg —
Subject Sertraline Small molecule 100 mg —
Subject Ziprasidone Small molecule 60 mg —
Subject Ziprasidone Small molecule 100 mg —
Subject Ziprasidone Small molecule 120 mg —
Subject Ziprasidone Small molecule 160 mg —

Indications